tailieuchung - Dose response of umeclidinium administered once or twice daily in patients with COPD: A randomised cross-over study

Đang chuẩn bị liên kết để tải về tài liệu:
Dose response of umeclidinium administered once or twice daily in patients with COPD: A randomised cross-over study

Tường Nguyên 23 14 pdf

Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ Tải xuống

Umeclidinium bromide (UMEC) is an inhaled long-acting muscarinic antagonist in development for chronic obstructive pulmonary disease (COPD). UMEC is a potent QD bronchodilator with geometric mean ED50 of 37 μg. A dose ordering over the range of UMEC 15.6–125 μg QD doses was observed, with UMEC 125 μg showing the greatest improvement in trough FEV1. |

Đang chuẩn bị liên kết để tải về tài liệu:
Dose response of umeclidinium administered once or twice daily in patients with COPD: A randomised cross-over study

Safety and pharmacodynamic dose response of short-term prednisone in healthy adult subjects: A dose ranging, randomized, placebo-controlled, crossover study

Response of fertility dose in citronella (Cymbopogon winterianus L.) intercropping with mustard (Brassica juncea)

Is more better? An analysis of toxicity and response outcomes from dose-finding clinical trials in cancer

GRcalculator: An online tool for calculating and mining dose–response data

Metabolic targeting of HIF-dependent glycolysis reduces lactate, increases oxygen consumption and enhances response to high-dose single-fraction radiotherapy in hypoxic solid tumors

The dose-response relationship between tobacco smoking and the risk of lymphomas: A case-control study

Tea consumption and the risk of five major cancers: A dose–response meta-analysis of prospective studies

A randomised dose-response study of prophylactic Methoxamine infusion for preventing spinal-induced hypotension during Cesarean delivery

Community Response to Road Traffic Noise in Hue City, Vietnam

RadFET dose response in the CHARM mixed-ﬁeld: FLUKA MC simulations

Đang chuẩn bị liên kết để tải về tài liệu: Dose response of umeclidinium administered once or twice daily in patients with COPD: A randomised cross-over study